Hansjoerg Keller

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9894337/publications.pdf Version: 2024-02-01



HANSIOEDC KELLED

#	Article	IF	CITATIONS
1	Matrigel 3D bioprinting of contractile human skeletal muscle models recapitulating exercise and pharmacological responses. Communications Biology, 2021, 4, 1183.	4.4	29
2	A Novel Microplate 3D Bioprinting Platform for the Engineering of Muscle and Tendon Tissues. SLAS Technology, 2018, 23, 599-613.	1.9	76
3	Class I and IIa Histone Deacetylases Have Opposite Effects on Sclerostin Gene Regulation. Journal of Biological Chemistry, 2014, 289, 24995-25009.	3.4	38
4	Reversing <i>LRP 5</i> -Dependent Osteoporosis and <i>SOST</i> Deficiency–Induced Sclerosing Bone Disorders by Altering WNT Signaling Activity. Journal of Bone and Mineral Research, 2014, 29, 29-42.	2.8	72
5	TGF-Î ² regulates sclerostin expression via the ECR5 enhancer. Bone, 2012, 50, 663-669.	2.9	56
6	<i>Mef2c</i> deletion in osteocytes results in increased bone mass. Journal of Bone and Mineral Research, 2012, 27, 360-373.	2.8	78
7	Parathyroid hormone (PTH)–induced bone gain is blunted in <i>SOST</i> overexpressing and deficient mice. Journal of Bone and Mineral Research, 2010, 25, 178-189.	2.8	234
8	Osteocyte Wnt/β-Catenin Signaling Is Required for Normal Bone Homeostasis. Molecular and Cellular Biology, 2010, 30, 3071-3085.	2.3	501
9	Does osteocytic SOST suppression mediate PTH bone anabolism?. Trends in Endocrinology and Metabolism, 2010, 21, 237-244.	7.1	114
10	Control of the <i>SOST</i> Bone Enhancer by PTH Using MEF2 Transcription Factors. Journal of Bone and Mineral Research, 2007, 22, 1957-1967.	2.8	233
11	Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Research, 2005, 15, 928-935.	5.5	399
12	SOST is a target gene for PTH in bone. Bone, 2005, 37, 148-158.	2.9	579